We measure linear optical dispersion, nonlinear refraction and two-photon absorption in a silicon waveguide at 1.54 μm wavelength. The total dispersion in the silicon waveguide was found to be −9.1 fs/(nm cm). At 1.54 μm wavelength, the two-photon absorption coefficient was found to be 0.45 cm/GW and a π phase shift from self-phase modulation was observed in optical pulses of 60 W peak-coupled power, generated from an amplified gain-switched laser diode.

No abstract

Objective: This study compared the efficacy of PF-based and CROSS-based neoadjuvant chemoradiotherapy for ESCC. Background: PF-based regimen has been a standard regimen for ESCC, but it has been replaced by the CROSS regimen in the past few years, despite no prospective head-to-head comparative study has been performed. Methods: This is a single center retrospective study. Records of all ESCC patients who have received neoadjuvant PF with 40 Gy radiotherapy in 20 daily fractions (PFRT Group) or CROSS with 41.4 Gy radiotherapy in 23 daily fractions (CROSS Group) during the period 2002 to 2019 were retrieved. Propensity score matching (1:1) was performed to minimize baseline differences. The primary and secondary endpoints were overall survival and clinicopathological response. Subgroup analysis (“CROSS Eligibility”) was performed based on tumor length, cT-stage, cM-stage, age, and performance status. Results: One hundred (out of 109) patients (CROSS group) and propensity score matched 100 (out of 210) patients (PFRT group) were included. Esophagectomy rates in CROSS and PFRT group were 69% and 76%, respectively (P = 0.268). R0 resection rates were 85.5% and 81.6% (P = 0.525) and the pathological complete remission rates were 24.6% and 35.5% (P = 0.154). By intention-to-treat, the median survival was 16.7 and 32.7 months (P = 0.083). For “CROSS Eligible subgroup,” the median survival of the CROSS and PFRT group was 21.6 versus 44.9 months (P = 0.093). Conclusions: There is no statistically difference in survival or clinicopathological outcome between both groups, but the trend favors PFRT. Prospective head-to-head comparison and novel strategies to improve the outcomes in resectable ESCC are warranted.

We propose and demonstrate label encoding-swapping and transmission for an orthogonally labeled packet by use of a 10-Gbit/s amplitude shift keying payload and a 2.5-Gbit/s polarization shift keying (PolSK) label. A simple scheme for demodulating and demultiplexing the PolSK label based on an injection-locked Fabry-Perot laser diode is described. The extinction ratio of the newly added PolSK label can be precisely controlled and maintained after the intermediate node.